SavedAdd your journal

Journals / Genel Tıp Dergisi / 1999 / Cilt: 9 - Sayı: 1

Severe fulminant hepatitis after a treatment of tuberculosis ( Case report )

Tüberküloz tedavisinde gelişen fulminan hepatit ( Olgu sunumu )

M. Emre ATABEK
Bülent ORAN
Pakize DEMİREZİCİ
Ümran ÇALIŞKAN
İbrahim ERKUL
Pages
23–26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Antituberculosis drugs causing liver damage should not be used together.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Isoniazid (INH) is a major hepatotoxic drug and with rifampicin (RIF) which is a powerful enzyme inducer may enhance the hepatotoxicity of INH.
📊
Key Findings & Data:Case report: We reported a patient who developed severe fulminant hepatitis after a treatment with INH for only 8 days combined with RIF and imipenem-cilastine.
💡
Conclusion & Impact:Conclusion: Antituberculosis drugs causing liver damage should not be used together.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç toksisitesi · Tüberküloz · İmipenem

Abstract

Objective: Isoniazid (INH) is a major hepatotoxic drug and with rifampicin (RIF) which is a powerful enzyme inducer may enhance the hepatotoxicity of INH. The prognosis is good in most cases. Case report: We reported a patient who developed severe fulminant hepatitis after a treatment with INH for only 8 days combined with RIF and imipenem-cilastine. Conclusion: Antituberculosis drugs causing liver damage should not be used together.

Özet

Amaç: (INH) majör hepatotoksik bir ilaçtır ve rifampisinle (RIF) birlikte kullanıldığı zaman RIF'in güçlü enzim indükleyici özelliği nedeniyle INH'ın hepatotoksisitesi artabilir. Birçok olguda prognoz iyidir. Olgu sunumu: RIF ve imipenem-cilastinle birlikte, sadece 8 günlük INH tedavisi sonrası ağır fulminant hepatit gelişen bir olgu sunuyoruz. Sonuç: Karaciğer hasarı yapan ilaçlar antitüberküloz ilaçlarla birlikte kullanılmamalıdır.

🔖

Cite This Article

ATABEK, M. E., ORAN, B., DEMİREZİCİ, P., ÇALIŞKAN, Ü., ERKUL, İ. (1999). Severe fulminant hepatitis after a treatment of tuberculosis ( Case report ). Genel Tıp Dergisi, Cilt: 9 - Sayı: 1, 23–26. https://ajindex.com/articles/225146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Starke JR. Tuberculosis. In: Behrman RE, Kliegman RM, Arvin AM, editors. Nelson textbook of pediatrics. 15th ed. Philadelphia: WB Saunders Company; 1996. p.834-46.
  2. Arky R, Davidson CS. Physicians’ Desk Reference (PDR) Product information, Primaxin (Merc), Montvale: Medical Economics Company; 1997. p.1770. Durand F, Jebrak G, Pessayre D, Fournier M, Bernua U. Hepatotoxicity of antitubercular treatments: Retionale for monitoring liver status. Drug Saf 1996;15:394-6.
  3. Canova CR, Kuhn M, Zellweger U, Reinhart WH. Fulminant, rapidly reversible hepatitis and life-threatening anaphlaxis following rifampicin in an HIV-positive female patient with latent adrenal cortex insufficiency. Schweiz Med Wochenschr 1996;126:392-5.
  4. Dutt AK, Moers D, Stead WW. Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin. Am Rev Respir Dis 1992; 145:1429-31.
  5. Turktas H, Unsal M, Tulek N, Oruc O. Hepatotoxicity of antituberculosis therapy (rifampicin isoniazid and pyrazinamid) or viral hepatitis. Tuber Lung Dis 1994;75:58-9.
  6. Westphal JF, Vetter D, Brogard JM. Hepatic side effects of antibiotics. J Antimicrob Chemother 1994;33:387-9.
  7. Moitinho E, Salmeron JM, Mas A, Bruguera M, Rodes J. Severe hepatotoxicity of tuberculostatic agents: Increase in the incidence. Gastroenterol Hepatol 1996;19:448-51.
  8. Singh J, Gark PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy: Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996;22:211-3.
  9. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TT, Lee SD. A prospective clinical study of isoniazid-rifampicin-pyrazinamide induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol1997;12:87-91.
  10. Ahonkhai VI, Cyhan GM, Wilson SE, Brown KR. Imipenem-cilastin in pediatric patients: An overview of safety and efficacy in studies conducted in the United States. Pediatr Infect Dis J 1989;8:740-3.
  11. Graziani AL, Gibson GA, MacGregor RR. Biliary excretion of imipenem - cilastin in hospitalized patients. J Antimicrob Agents Chemother 1987;31:1718-27.